EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Gil D Rabinovici, David S Knopman, Javier Arbizu, Tammie L S Benzinger, Kevin J Donohoe, Oskar Hansson, Peter Herscovitch, Phillip H Kuo, Jennifer H Lingler, Satoshi Minoshima, Melissa E Murray, Julie C Price und 4 weitere

Journal of Nuclear Medicine · 2025-06 · 66 (Supplement 2) · S5-S31

DOI: 10.2967/jnumed.124.268756 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.01.2025. Verfasst von Gil D Rabinovici und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology and Department of Radiology and Biomedical Imaging, University of California at San Francisco, San Francisco, California; gil…. Hauptthemen laut MEDLINE: tau Proteins, Positron-Emission Tomography, Alzheimer Disease, Amyloid. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 261 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Alzheimer’s Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET.

Methods

The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand-alone modalities.

Results

For amyloid PET, 7 scenarios were rated as appropriate, 2 as uncertain, and 8 as rarely appropriate. For tau PET, 5 scenarios were rated as appropriate, 6 as uncertain, and 6 as rarely appropriate.

Conclusion

AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsPositron-Emission TomographyAlzheimer DiseaseAmyloidNuclear MedicineMolecular ImagingHumansSocieties, Medical

Stichwörter der Autor:innen

Alzheimer diseasePETPET imagingamyloid PETappropriate use criteriabiomarkersbrain pathologyclinical carecognitive impairmentdementiadiagnosisearly detectionmemory disordersmolecular imagingneuroimaging

Substanzen

tau ProteinsAmyloid

Autor:innen und Institutionen

  • Department of Neurology and Department of Radiology and Biomedical Imaging, University of California at San Francisco, San Francisco, California; gil.rabinovici@ucsf.edu cweber@alz.org.
  • Mayo Clinic Neurology and Neurosurgery, Rochester, Minnesota.
  • Department of Nuclear Medicine, University of Navarra Clinic, Pamplona, Spain.
  • Mallinckrodt Institute of Radiology, School of Medicine, Washington University in St. Louis, St. Louis, Missouri; Knight Alzheimer's Disease Research Center, School of Medicine, Washington University in St. Louis, St. L…
  • Nuclear Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.

Förderung

  • NIA NIH HHS

Zitieren

APA

Rabinovici, G. D., Knopman, D. S., Arbizu, J., Benzinger, T. L. S., Donohoe, K. J., Hansson, O., Herscovitch, P., Kuo, P. H., Lingler, J. H., Minoshima, S., Murray, M. E., Price, J. C., Salloway, S. P., Weber, C. J., Carrillo, M. C., & Johnson, K. A. (2025). Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Journal of Nuclear Medicine, 66(Supplement 2), S5-S31. https://doi.org/10.2967/jnumed.124.268756

Vancouver

Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Journal of Nuclear Medicine. 2025;66(Supplement 2):S5-S31. doi:10.2967/jnumed.124.268756

BibTeX
@article{Rabinovici2025,
  author = {Rabinovici, Gil D and Knopman, David S and Arbizu, Javier and Benzinger, Tammie L S and Donohoe, Kevin J and Hansson, Oskar and Herscovitch, Peter and Kuo, Phillip H and Lingler, Jennifer H and Minoshima, Satoshi and Murray, Melissa E and Price, Julie C and Salloway, Stephen P and Weber, Christopher J and Carrillo, Maria C and Johnson, Keith A},
  title = {Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {Supplement 2},
  pages = {S5--S31},
  doi = {10.2967/jnumed.124.268756}
}
Kostenlos starten →